Sarcoma Nomograms: Extremity/Truncal Liposarcoma: Disease-Specific Death and Local Recurrence

In the U.S.

Prediction Tools: DisclaimerThe prediction tools (also known as prognostic nomograms) available on Memorial Sloan Kettering Cancer Center’s (“MSK”) website use algorithms or mathematical formulas to estimate the probability of a particular outcome. They are for general health information only. The tools have not been reviewed or approved by any regulatory agencies in the United States or elsewhere, and are not intended for use as a medical device. The tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem. Users of the prediction tools should not rely on any resulting information for their own health problems. Outputs from these tools are estimates based on survival models built from databases of large numbers of patients. The predictions suggested by these tools may not apply to a given individual. A licensed clinician should always be consulted for any health problem(s) or medical condition(s).Users agree to use the prediction tools for educational and/or research purposes only, and not for any commercial purposes, including the distribution, licensing, or sale of their content to any other person or entity, whether alone or in combination with other materials, or the incorporation of any of the prediction tools into any commercial product.MSK makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSK does not assume any risk whatsoever for use of the prediction tools or the information contained therein. As health-related information changes frequently, information contained in the prediction tools may be outdated, incomplete, or incorrect.Use of the prediction tools does not create an express or implied physician-patient relationship. MSK does not endorse or claim validity for the prediction tools found on MSK’s website. The activities and products of MSK and its developers and agents (collectively MSK) are not endorsed by past, present, or future employers. MSK does not record specific prediction tool user information and does not contact users of the prediction tools.Users are advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue that users might have at any time, now or in the future. In using the prediction tools, users agree that neither MSK nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to the use of any information resulting from the prediction tools on MSK’s website.

Our extremity/truncal liposarcoma nomogram is a tool designed to predict the prognosis of a patient with extremity/truncal liposarcoma, the most common soft tissue sarcoma, after the primary tumor has been removed by surgery. This tool predicts the likelihood of dying from extremity/truncal liposarcoma three years, five years, and ten years after surgical treatment for the disease, based on tumor characteristics, such as the specific liposarcoma histologic subtype. This tool also predicts the likelihood of extremity/truncal liposarcoma returning at the site of initial surgery three years, five years, and ten years after the tumor is removed through surgery.

This nomogram specifically does NOT include retroperitoneal liposarcoma. For patients with retroperitoneal sarcoma, please refer to the sarcoma-specific death and local recurrence nomogram published Annals in Surgery.

Results produced by this tool are based on data from patients treated at MSK, a large research institution with surgeons who perform a high volume of liposarcoma procedures. All results must be understood in the context of each patient’s specific treatment plan. Patients and caregivers using this tool should discuss the result with the patient’s physician.

To gather the information required to use this nomogram, use our worksheet.

Enter Your Information

All fields are required unless noted optional

What was the size of your primary tumor? cm (1 to 32)

What was the histologic variant (subtype) of the tumor?

What is histology?: Histology refers to the exact type of cancer based on examination of the tumor tissue under the microscope. Liposarcoma is classified as Well-differentiated; Myxoid; Dedifferentiated; Round Cell; or Pleomorphic.

Were the surgical margins positive?

Yes

What are surgical margins?: Margin refers to the edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as microscopically positive or involved when the pathologist finds traces of cancer cells at the edge of the tissue. The margin is described as grossly positive if the surgeon was unable to remove the entire tumor or all parts of the tumor, implying that a substantial part of the tumor remains in the body.

Clear

Supporting Publications

Extremity/Truncal Liposarcoma Specific Death After Surgery

Probability of not surviving to ten years after surgery

Bartlett EK, Curtin CE, Seier K, Qin LX, Hameed M, Yoon SS, Crago AM, Brennan MF, Singer S. Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. Ann Surg. 2021 Jun 1;273(6):1189-1196. doi: 10.1097/SLA.0000000000003453. PMID: 31283560; PMCID: PMC7561049.

Extremity/Truncal Liposarcoma Local Recurrence

Probability that extremity/truncal liposarcoma will return within three years, five years, and ten years after surgery

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We’re here for you.

Make an appointment

Speak to a care advisor

We treat every type of cancer, including the most important one: yours.

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.

Enter Your Information

Supporting Publications

Extremity/Truncal Liposarcoma Specific Death After Surgery

Extremity/Truncal Liposarcoma Local Recurrence